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OBJECTIVES: The aim of the study is to investigate the effect
of the implementation of Diagnosis Related Groups (DRGs) on
the average length of stay in the rheumatology departments in
Hungary. METHODS: The data derive from the ﬁnancial data-
base of the National Health Insurance Fund Administration
(OEP) of Hungary covering the period of 1995–2004. All the
rheumatology departments in Hungary are included into the
study. For the analyses we choose the average length of stay
(ALOS). We compared the changes in the average length of stay
of rheumatology departments with the national average of all
medical specialities. During the period of 1995–2004 there were
used 7 different versions of the Hungarian DRG. RESULTS: The
average length of stay was 14.88 days in rheumatology in 1995
while it was on average 9.68 days for all medical specialities. For
2004 the average length of stay decreased by 3.85 days to 11.03
days in rheumatology and by 2.72 days to 6.96 days in all
medical specialities. The gap between rheumatology and the
national average of all medical specialities has been also closing
up from a difference of 5.20 days in 1995 to 4.07 days in 2004.
According to progressivity levels we found the longest average
length of stay in national medical institutes providing higher (ter-
tiary) level of medical care while the shortest ALOS was observed
in city hospitals providing basic hospital care. CONCLUSIONS:
We found that although the average length of stay of all medical
specialities decreased between 1995–2004, the rheumatology
departments underwent a signiﬁcant reduction of their average
length of stay. After the implementation of the Diagnosis Related
Groups (DRG) system the hospitals realized ﬁnancial incentives
in order to reduce their costs. In our investigation we managed
to conﬁrm that the efﬁciency of rheumatology care improved
during this decade.
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PRICES OF GENERIC DRUGS IN FINLAND VS. EUROPE
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OBJECTIVES: To compare price level of generic drugs in Finland
and in Europe on average and to ﬁnd out whether price level of
generics decreases faster or slower in Finland compared to
Europe. METHODS: Active substances that had over 2%
market share of generic market in Finland in 2005 were included.
Top 16 most sold substances fulﬁlled this criterion and accounted
for 50.6% of the total generic market. To analyze the rate of
price deﬂation the time from the launch date of the ﬁrst generic
product of each substance was used as an estimate of the time
generic competition has prevailed. The same methods were used
to compare Finnish prices to those of UK, The Netherlands and
Denmark on a country level. RESULTS: Finnish prices were
below European average in 12 cases out of 16. The analysis of
the rate of price decrease suggests that Finnish prices may decline
faster after generic launch than in Europe. In the country spe-
ciﬁc comparison prices in Finland were lower than in UK, The
Netherlands and Denmark in 72%, 75% and 33% of packs
included, respectively. Compared to Finland, prices seem to
decrease more rapidly in Denmark but slower in The Nether-
lands. In UK prices are at a higher level than in Finland at all
times including the launch of generic competition. CONCLU-
SION: Prices of generic drugs appear to be lower in Finland than
in Europe on average. This cross sectional analysis suggests that
prices in Finland decline more rapidly after the generic launch
than in other European countries on average. However, there is
considerable variation in Europe in respect of generic price level
and rate of price decrease, as our country speciﬁc examples
show.
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A 5% price cut of all reimbursed medicines was enforced at the
beginning of 2006 in Finland to control increasing drug costs.
OBJECTIVES: To estimate the signiﬁcance of price development
to rising drug costs by describing the development of drug whole-
sale price indices in Finland in 1980–2005. METHODS: Price
indices covering study period (The Helsinki Research Institute
for Business Administration [1980–1990], IMS [1991–1994] and
Statistics Finland [1995–2005]) were merged into two index
clusters (1980 = 100 and 1990 = 100). The latter enables more
precise classiﬁcation according to reimbursement categories.
Real price indices were produced by adjusting nominal indices
with Consumer Price Index (CPI, Statistics Finland) and its sub-
index Consumer Price Index for Health Care (CPI-H, Statistics
Finland). RESULTS: In 2005, the index (1980 = 100) for all
drugs was 164 (CPI adjusted 63; CPI-H adjusted 32) and for
basic refund category 137 (53; 26), respectively. The respective
ﬁgures in 1990 = 100 index were: all drugs 105 (82; 58), pre-
scription based 98 (76; 54), reimbursed 92 (72; 51), Basic
Refund (‘50%’) 94 (73; 52), Lower Special Refund (‘75%’) 85
(66; 47) and Higher Special Refund (‘100%’) 100 (78; 55).
CONCLUSIONS: Nominal drug wholesale prices have increased
in Finland, but real prices have constantly decreased. Real prices
(CPI-adjusted; CPI-H-adjusted in parenthesis) of all drugs have
decreased 37% (68%) since 1980, or 18% (42%) since 1990.
For reimbursed drugs the development has been more dramatic;
in Basic Refund category real prices have decreased 47% (74%)
since 1980, and 27% (48%) since 1990. From that point of view
it seems that rising drug costs can not be explained with price
development and that grounds for mandatory price cuts are not
sustainable.
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Controlling pharmaceutical expenditures within health care
budgets is of particular interest to governments. Despite incen-
tives for substitution to cheaper generic products, these expen-
ditures keep increasing. The Dutch government suggested
therapeutic substitution to be responsible for such increasing
expenditures. OBJECTIVES: To investigate the inﬂuence and
economic impact of therapeutic substitution around patent
expiry. METHODS: Analyses were done for proton pump
inhibitors (PPIs) with data obtained from the InterAction Data-
Base (IADB), comprising pharmacy dispensing records of
approximately 500,000 patients of the Northern and Eastern
part of The Netherlands. Trends in PPI-use were presented quar-
terly between 2000–2003. To analyse differences in switching
patterns for omeprazole (patent expiry: april 2002), two cohorts
were deﬁned and followed for two years: omeprazole users
before (cohort 1) and after (cohort 2) patent expiry. Survival
analysis was conducted using patient-speciﬁc data to identify
‘switchers’ from and ‘survivors’ on omeprazole. RESULTS: PPI-
use increased over time, with a downward trend in proportional
omeprazole use compared to other PPIs. Totals of 5913 and 7369
patients could be included in cohort 1 and 2, respectively. During
follow-up, 495 (8%) patients in cohort 1 and 998 (14%) patients
in cohort 2 switched from omeprazole to another PPI (p <
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0.001). For every 6 patients switching in cohort 1, 10 patients
switched in cohort 2 (hazard ratio: 0.62, 95% CI: 0.57–0.69).
The introduction of generic omeprazole resulted in decreasing
expenditures for omeprazole (−€140 million; −56%) and for all
PPIs (−€52 million; −16%) between 2001–2004. However, some
savings have been missed due to increased switching from the
generic product. Further results will be presented on statins of
which analyses are currently conducted. CONCLUSIONS: After
patent expiry, more patients switch from omeprazole to another
PPI. It is however debatable whether a 5% increase in ‘switch-
ers’ is relevant in the light of enormous decreased expenditures
due to generic substitution.
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ANALYSIS OF COST OF ILLNESS IN THE NETHERLANDS IN
2003: INTEGRATING NATIONAL AND INTERNATIONAL
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OBJECTIVES: To determine the demands on health care
resources caused by disease, age and gender and to demonstrate
the importance of the perspective on health expenditure
(national versus international). METHODS: A generic top-down
cost-of-illness analysis was performed for The Netherlands.
Expenditure per provider in 2003 was known for three perspec-
tives on health care costs: the OECD’s System of Health
Accounts (SHA) and two national perspectives. Data on health
care use were collected from 70 registries of which the most
important had national coverage. These were mapped on expen-
diture to estimate cost of illness and enabled analysis in six
dimensions: provider, health care function, source of funding,
age, gender and disease. Outcome measures were total costs and
costs per capita. RESULTS: Mental diseases represent the most
expensive main diagnostic group (22% of total costs). Heart dis-
eases come second (9.2%). Neoplasms come on a 7th place
(4.1%). The three perspectives showed minor differences in
ranking of disease groups. Total costs differed widely between
perspectives: €43.7 to €57.5 billion (9–12% GDP), the higher
estimate based on the perspective of the Dutch National Health
Accounts, the lower on the perspective of the Dutch ministry of
Health. The international SHA-perspective came close in total
costs to the ministry of Health estimate (€45.1 billion), but had
a radical different composition. Cost increase by age, sharply
from 65+ onwards until €50,000 per citizen for the oldest old.
In the SHA-approach the increase is less steep because of the
exclusion of speciﬁc health provisions for Dutch elderly. CON-
CLUSIONS: The perspective on health expenditure has an
important inﬂuence on coi-estimates, especially for per capita
costs and to a lesser extent for the relative expenditure on par-
ticular diseases. Insight in the differences between perspectives
enables better national and international comparisons between
coi-studies.
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NUTRICORE®: COST-EFFECTIVENESS-ANALYSIS (CE) OF AN
EVIDENCE BASED CLINICAL NUTRITION CONCEPT IN
CORRELATION WITH RELEVANT CLINICAL OUTCOMES IN
HOSPITALIZED MALNOURISHED PATIENTS BY RISK-
ADJUSTMENT OF DIAGNOSIS BASED SEVERITY OF DISEASE
Fischer FJ, Goeke T, Gohlke A
Schellen und Partner GmbH, Düsseldorf, NRW, Germany
Current clinical data show that every third hospitalized patient
in Germany is malnourished. This indicates a need for manda-
tory nutrition status screening and evidence based clinical nutri-
tion. The cost-effectiveness-estimate of this concept has not yet
been evaluated by a diagnosis based severity-of-disease risk-
adjustment. NUTRICORE is the ﬁrst study worldwide, using the
predictive scale of Disease Staging to get valid data on risk-
adjusted clinical and economic outcomes in the ﬁeld of clinical
nutrition research on large patient populations (>10,000).
OBJECTIVES: To show a positive correlation of an evidence
based clinical nutrition concept on clinical and economic out-
comes in malnourished hospitalized patients by risk-adjustment
on severity of disease and corresponding cost-effectiveness-
analysis. METHODS: NUTRICORE SP1 is a prospective con-
trolled interventional multicenter based clinical trial with more
than 10,000 patients from German Hospitals. The nutrition
status of each patient is screened and combined with clinical
data, utilization data and direct costs on the basis of clinical
homogenous patient clusters. The risk adjustment scales can be
run by routine data sets from German inpatient G-DRG system
2006. In the control period starting in June 2006 the effects of
usual nutrition care are documented. Starting the intervention
period in October 2006 an implementation of an interdiscipli-
nary evidence-based guideline for screening and clinical nutrition
will be introduced in each participating hospital. RESULTS:
NUTRICORE SP1 has been piloted in two 600-bed-hospitals in
Germany during 2005, showing a signiﬁcant reduction of costs
for clinical nutrition by €152,544.00 per year for a risk-adjusted
patient population of €38,004 cases in total. CONCLUSIONS:
The study NUTRICORE SP1 is intended to show signiﬁcant clin-
ical improvements and signiﬁcant cost-effectiveness by the imple-
mentation of an evidence based nutrition concept within clinical
homogenous patient groups leading to reduction of Length of
Stay (LOS), Inpatient Mortality, Complications-of-Care, hospi-
tal readmission.
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EXPENDITURE: EVALUATION OF SUPPLY MEASURES
Magem Luque D, Gilabert i Perramon A
Catalan Health Service, Barcelona, Spain
OBJECTIVES: To analyze the evolution of the pharmaceutical
public expenditure and to evaluate the impact of supply mea-
sures of restraint over its growth. METHODS: Time series analy-
sis through linear autoregressive multivariate models (January
1999–June 2005). Source: monthly pharmaceutical invoices.
Dependent variables: total public expenditure (E), number of
prescriptions adjusted by days (P/d), and average public expen-
diture per prescription (E/P). Independent variables analyzed:
trend, seasonal variation, cycles, number of days and lags when
necessary. Impacts analyzed: introduction of maximum margins
for wholesalers and chemists’ and discounts over chemists’
turnovers (D), and introduction of two reference pricing groups
(RPG1 & RPG2 respectively). Lags are also introduced when
residual autocorrelation occurs. Models are validated through
normal contrast and no-correlation of residual. RESULTS:
Adjusted R2 are 0.818, 0.684 and 0.814 in E, P/d and E/P when
trend is considered as unique variable. There are no seasonal
variation at any time series (p > 0.1) when this variable is related
to four seasons as a categorical variable. However, August has
been entered in E and P/d models as a dichotomic variable (p <
0.0001 & p < 0.01). Number of days also entered in E model 
(p < 0.0001). Annual cycle is observed in P/d and E/P model 
(p < 0.05) and half-yearly and cuatrimestral cycles also entered
in P/d model (p < 0.05). Two supply measures present impacts
at the short term. D has entered in the three models: E (p < 0.001;
Beta: −8,733,966), P/d (Beta: −13,100) and E/P (Beta: −0.18) 
(p < 0.05 both). RPG2 has been also considered in E (Beta: 
